GE HealthCare Technologies Inc.GEHC

NasdaqGS•Healthcare•Medical Devices

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Price & Volume

Key Metrics at a Glance (as of December 2025)

Market Cap: $3.07T
TTM Revenue: $20.63B
TTM EBITDA: $3.34B
P/E Ratio: 1383.6x
Operating Margin: 14.5%
Free Cash Flow: $1.32B

Financial Analysis

GE HealthCare Technologies Inc. (GEHC) reported trailing twelve months (TTM) revenue of $20.63B as of December 2025, which represents a 4.8% increase year-over-year. The company's operating margin has contracted to 14.5% from 15.1% a year ago. In terms of profitability, GEHC generated $2.22B in net income. Valuation-wise, the stock trades at a P/E ratio of 1383.6x and a Price-to-Sales (P/S) ratio of 148.9x. The company generated $1.32B in free cash flow over the last twelve months, indicating its ability to reinvest in growth or return capital to shareholders. Data based on the most recent quarterly reports.